Top-Rated StocksTop-RatedNASDAQ:PGNY Progyny (PGNY) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free PGNY Stock Alerts $32.40 -0.66 (-2.00%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$32.34▼$33.3050-Day Range$31.88▼$41.3852-Week Range$29.44▼$44.95Volume625,184 shsAverage Volume786,847 shsMarket Capitalization$3.11 billionP/E Ratio52.26Dividend YieldN/APrice Target$48.30 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Progyny alerts: Email Address Progyny MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside49.1% Upside$48.30 Price TargetShort InterestBearish7.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 8 Articles This WeekInsider TradingSelling Shares$4.57 M Sold Last QuarterProj. Earnings Growth38.57%From $0.70 to $0.97 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.30 out of 5 starsMedical Sector131st out of 910 stocksMiscellaneous Health & Allied Services, Not Elsewhere Classified Industry2nd out of 6 stocks 4.5 Analyst's Opinion Consensus RatingProgyny has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageProgyny has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.87% of the float of Progyny has been sold short.Short Interest Ratio / Days to CoverProgyny has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Progyny has recently increased by 5.32%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProgyny does not currently pay a dividend.Dividend GrowthProgyny does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PGNY. Previous Next 2.5 News and Social Media Coverage News SentimentProgyny has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Progyny this week, compared to 4 articles on an average week.Search Interest6 people have searched for PGNY on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,570,131.00 in company stock.Percentage Held by Insiders12.30% of the stock of Progyny is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Progyny are expected to grow by 38.57% in the coming year, from $0.70 to $0.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Progyny is 52.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.23.Price to Earnings Ratio vs. SectorThe P/E ratio of Progyny is 52.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 214.08.Price to Earnings Growth RatioProgyny has a PEG Ratio of 1.35. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioProgyny has a P/B Ratio of 5.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad AltimetryMan Who Predicted 2008: “This Will be Worse.”He Was China's Second In Command – Then He Blew The Whistle Want to know what's really ahead for China's "economic miracle?" Beijing's second most powerful politician tried to warn us – and he may have paid with his life. And that's just one reason why the smart money is fleeing China for safer shores. U.S. Pentagon consultant Joel Litman has the full story – and a list of U.S. companies you'll want to buy now. Click here for details. About Progyny Stock (NASDAQ:PGNY)Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.Read More PGNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PGNY Stock News HeadlinesApril 4, 2024 | insidertrades.comProgyny, Inc. (NASDAQ:PGNY) Chairman Sells $37,520.00 in StockMarch 30, 2024 | insidertrades.comProgyny, Inc. (NASDAQ:PGNY) Chairman David J. Schlanger Sells 71,272 SharesApril 23, 2024 | Altimetry (Ad)Man Who Predicted 2008: “This Will be Worse.”He Was China's Second In Command – Then He Blew The Whistle Want to know what's really ahead for China's "economic miracle?" Beijing's second most powerful politician tried to warn us – and he may have paid with his life. And that's just one reason why the smart money is fleeing China for safer shores. U.S. Pentagon consultant Joel Litman has the full story – and a list of U.S. companies you'll want to buy now. March 28, 2024 | insidertrades.comProgyny, Inc. (NASDAQ:PGNY) Chairman Sells $97,777.05 in StockMarch 26, 2024 | insidertrades.comDavid J. Schlanger Sells 5,826 Shares of Progyny, Inc. (NASDAQ:PGNY) StockApril 20, 2024 | finance.yahoo.comProgyny, Inc. (PGNY)April 19, 2024 | americanbankingnews.comProgyny (NASDAQ:PGNY) Rating Reiterated by Truist FinancialApril 17, 2024 | finance.yahoo.comProgyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building CareApril 23, 2024 | Altimetry (Ad)Man Who Predicted 2008: “This Will be Worse.”He Was China's Second In Command – Then He Blew The Whistle Want to know what's really ahead for China's "economic miracle?" Beijing's second most powerful politician tried to warn us – and he may have paid with his life. And that's just one reason why the smart money is fleeing China for safer shores. U.S. Pentagon consultant Joel Litman has the full story – and a list of U.S. companies you'll want to buy now. April 17, 2024 | globenewswire.comProgyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building CareApril 16, 2024 | finance.yahoo.comProgyny, Inc. (PGNY) Interactive Stock Chart - Yahoo FinanceApril 10, 2024 | nasdaq.comBenjamin Graham Detailed Fundamental Analysis - PGNYApril 5, 2024 | investing.comProgyny CFO sells over $419k in company stockApril 5, 2024 | investing.comProgyny executive chairman sells $37,522 in stockApril 4, 2024 | globenewswire.comProgyny and RESOLVE to Honor National Infertility Awareness Week® with Events Spanning Coast to CoastApril 3, 2024 | finance.yahoo.comInsider Sell: President Michael Sturmer Sells Shares of Progyny Inc (PGNY)March 30, 2024 | finance.yahoo.comExecutive Chairman David Schlanger Sells 71,272 Shares of Progyny Inc (PGNY)March 28, 2024 | finance.yahoo.comExecutive Chairman David Schlanger Sells Shares of Progyny Inc (PGNY)March 18, 2024 | globenewswire.comProgyny, Inc. to Present at KeyBanc Life Sciences & MedTech Investor ForumMarch 16, 2024 | finance.yahoo.comPGNY Apr 2024 20.000 callMarch 16, 2024 | finance.yahoo.comPGNY Apr 2024 55.000 callMarch 16, 2024 | finance.yahoo.comPGNY Apr 2024 30.000 callMarch 16, 2024 | ca.finance.yahoo.comPGNY Apr 2024 40.000 putMarch 15, 2024 | seekingalpha.comProgyny: Long-Term Outlook Remains Positive, Reiterate BuyMarch 15, 2024 | cnbc.comThis overlooked corner of women's health could be a $350 billion market opportunityMarch 15, 2024 | msn.com3 Quality Small Caps Available at a Discount Amid Russell 2000 CorrectionMarch 14, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Progyny (PGNY)See More Headlines Receive PGNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/23/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:PGNY CUSIPN/A CIK1551306 Webwww.progyny.com Phone212-888-3124FaxN/AEmployees563Year Founded2008Price Target and Rating Average Stock Price Target$48.30 High Stock Price Target$57.00 Low Stock Price Target$43.00 Potential Upside/Downside+46.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.62 Trailing P/E Ratio53.32 Forward P/E Ratio47.23 P/E Growth1.35Net Income$62.04 million Net Margins5.70% Pretax Margin6.49% Return on Equity12.64% Return on Assets8.82% Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio3.44 Sales & Book Value Annual Sales$1.09 billion Price / Sales2.92 Cash Flow$0.68 per share Price / Cash Flow48.72 Book Value$5.77 per share Price / Book5.73Miscellaneous Outstanding Shares96,110,000Free Float84,288,000Market Cap$3.18 billion OptionableOptionable Beta1.48 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. David J. Schlanger (Age 65)Executive Chairman Comp: $510.41kMr. Peter Anevski (Age 57)CEO & Director Comp: $1.01MMr. Michael Sturmer (Age 47)President Comp: $761.5kMr. Mark S. Livingston (Age 58)Chief Financial Officer Comp: $693.87kMs. Allison Swartz (Age 34)General Counsel & Secretary Comp: $173.35kMr. Steven LeistChief Technology OfficerMr. James HartVice President of Investor RelationsMs. Risa FisherChief Marketing OfficerMs. Cassandra PrattChief Human Resources OfficerMs. Julie StadlbauerChief Business Development OfficerMore ExecutivesKey CompetitorsSotera HealthNASDAQ:SHCagilon healthNYSE:AGLTivity HealthNASDAQ:TVTYAmerican Renal AssociatesNYSE:ARAOntrakNASDAQ:OTRKView All CompetitorsInsiders & InstitutionsAmalgamated BankSold 7,969 shares on 4/23/2024Ownership: 0.045%Wesbanco Bank Inc.Bought 28,169 shares on 4/23/2024Ownership: 0.029%Louisiana State Employees Retirement SystemBought 600 shares on 4/23/2024Ownership: 0.025%KLR Investment Advisors LLCBought 918 shares on 4/23/2024Ownership: 0.008%Norden Group LLCBought 14,840 shares on 4/19/2024Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions PGNY Stock Analysis - Frequently Asked Questions Should I buy or sell Progyny stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PGNY shares. View PGNY analyst ratings or view top-rated stocks. What is Progyny's stock price target for 2024? 10 Wall Street research analysts have issued 1-year price targets for Progyny's stock. Their PGNY share price targets range from $43.00 to $57.00. On average, they anticipate the company's stock price to reach $48.30 in the next year. This suggests a possible upside of 49.1% from the stock's current price. View analysts price targets for PGNY or view top-rated stocks among Wall Street analysts. How have PGNY shares performed in 2024? Progyny's stock was trading at $37.18 at the start of the year. Since then, PGNY shares have decreased by 12.9% and is now trading at $32.40. View the best growth stocks for 2024 here. When is Progyny's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our PGNY earnings forecast. How were Progyny's earnings last quarter? Progyny, Inc. (NASDAQ:PGNY) announced its quarterly earnings results on Tuesday, February, 27th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.04. The business had revenue of $269.94 million for the quarter, compared to the consensus estimate of $274.08 million. Progyny had a trailing twelve-month return on equity of 12.64% and a net margin of 5.70%. The firm's revenue for the quarter was up 26.0% on a year-over-year basis. During the same period last year, the firm earned $0.03 EPS. What ETFs hold Progyny's stock? ETFs with the largest weight of Progyny (NASDAQ:PGNY) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), Janus Henderson Small Cap Growth Alpha ETF (JSML), SPDR S&P Health Care Services ETF (XHS), BNY Mellon Women's Opportunities ETF (BKWO), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Thrivent Small-Mid Cap ESG ETF (TSME), AdvisorShares Alpha DNA Equity Sentiment ETF (SENT) and Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD). What guidance has Progyny issued on next quarter's earnings? Progyny issued an update on its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of 0.330-0.350 for the period, compared to the consensus estimate of 0.180. The company issued revenue guidance of $285.0 million-$292.0 million, compared to the consensus revenue estimate of $314.0 million. What is David Schlanger's approval rating as Progyny's CEO? 25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees. What other stocks do shareholders of Progyny own? Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD). When did Progyny IPO? Progyny (PGNY) raised $150 million in an IPO on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers. Who are Progyny's major shareholders? Progyny's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Congress Asset Management Co. MA (1.05%), Deepwater Asset Management LLC (0.41%), International Assets Investment Management LLC (0.16%), Congress Wealth Management LLC DE (0.16%), Los Angeles Capital Management LLC (0.05%) and Amalgamated Bank (0.05%). Insiders that own company stock include Cheryl Scott, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Kevin K Gordon, Mark S Livingston, Michael E Sturmer, Norman Payson, Peter Anevski, Robert Michael Floyd and Tpg Gp A, Llc. View institutional ownership trends. How do I buy shares of Progyny? Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PGNY) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryGreat Crypto BullWeiss RatingsThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progyny, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
